Vineti
Orchestrating personalized cell & gene therapy treatments for cancers & rare diseasesPrincipal Product Designer
2016-2022 | San Francisco, then nomadic
Orchestrating personalized cell & gene therapy treatments for cancers & rare diseases
Vineti was founded to solve the key challenges faced by patients, medical providers, pharmaceutical companies, and regulators in the delivery and commercialization of personalized medicine. Over six years, Vineti became the proven clinical-to-commercial platform for cell & gene therapy supply chain management.
Cell & Gene Therapy
Cell & gene therapies (CGT) are biologic drugs manufactured using the cells (blood or tissue) of a patient. They involve some of the most complex workflows in medicine, and require careful tracking across a series of locations.
Solution
Vineti built a platform for clinical and commercial cell & gene therapy supply chain management. The Dominos Pizza TrackerTM for cell therapies, if you will.
Impact
Vineti’s platform supported therapies across 26 disease indications, delivering treatments to ~5,000 patients before exit.
5k patient treatments delivered 16 pharma company customers 26 disease indications
Exit
Software acquired by Johnson & Johnson to continue supporting their global commercial therapy rollouts and ongoing clinical trials.
Team
Role
Principal Product Designer. From the ground up, researched, designed, prototyped, expanded and scaled the configurable, cross-channel patient treatment logistics platform. Worked with balanced teams and mentored growing design team throughout.
Vineti posts
Enterprise & Platforms & Regulation, oh my!
Groktalk series hosted by Groksmith in Yerevan, Armenia
Chain of Custody Handoff Patterns
Design 4 Healthcare lightning talks event at Vineti's offices in San Francisco
End-to-end platform patterns
Context: Extending platform functionality and establishing configurable patterns.
Impact: Expanded coverage to any autologous customer, launched a reusable baseline offering.
Comics translation to cancer treatments, a year in review
For my work life, 2016 was a year of transitions and contrasts.
Zero to MVP
Context: Enabling first pharma customer to get FDA approval for commercial scale launch of 72% efficacy leukemia treatment.
Impact: Delivered ~4,000 patient treatments, while establishing the foundation of Vineti's future platform.